Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Fiche publication
Date publication
août 2022
Journal
Journal of hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOULAGNON-ROMBI Camille
Tous les auteurs :
Calderaro J, Di Tommaso L, Maillé P, Beaufrère A, Nguyen CT, Heij L, Gnemmi V, Graham RP, Charlotte F, Chartier S, Wendum D, Vij M, Allende D, Diaz A, Fuster C, Rivière B, Herrero A, Augustin J, Evert K, Calvisi DF, Leow WQ, Wai Leung HH, Bednarsch J, Boleslawski E, Rela M, Wing-Hung Chan A, Forner A, Reig M, Pujals A, Favre L, Allaire M, Scatton O, Uguen A, Trépo E, Sanchez LO, Chatelain D, Remmelink M, Boulagnon-Rombi C, Bazille C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Kather JN, Gouw ASH, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Nault JC, Laurent A, Amaddeo G, Regnault H, de Martin E, Sempoux C, Navale P, Shinde J, Bacchuwar K, Westerhoff M, Cheuk-Lam Lo R, Sebbagh M, Guettier C, Lequoy M, Komuta M, Ziol M, Paradis V, Shen J, Caruso S
Lien Pubmed
Résumé
Combined Hepatocellular-Cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer (PLC) associated with a poor prognosis. Given the challenges in its identification and its clinical implications, biomarkers are critically needed. We aimed to investigate the diagnostic and prognostic value of the immunohistochemical expression of Nestin, a progenitor cell marker, in a large multicentric series of PLC.
Mots clés
cancer, cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, hepatocellular carcinoma, liver, nestin
Référence
J Hepatol. 2022 08 17;: